However, when analyzed in a specific disease context, elevated GDF15 in late-onset MADD patients with a relatively clean clinical background can serve as a powerful indicator to assist in the disease diagnosis, and be used as a monitoring indicator in follow-up assessment to evaluate disease recovery. This evidence concerns the gene GDF15 and multiple acyl-CoA dehydrogenase deficiency.